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AbstrACt
Objective To develop a feasible model for monitoring short-
term outcome of clinical care trajectories for hospitals in the 
Netherlands using data obtained from hospital information 
systems for identifying hospital variation.
study design Retrospective analysis of collected data 
from hospital information systems combined with clinical 
indicator definitions to define and compare short-term 
outcomes for three gastrointestinal pathways using the 
concept of Textbook Outcome.
setting 62 Dutch hospitals.
Participants 45 848 unique gastrointestinal patients 
discharged in 2015.
Main outcome measure A broad range of clinical 
outcomes including length of stay, reintervention, 
readmission and doctor–patient counselling.
results Patients undergoing endoscopic retrograde 
cholangiopancreatography (ERCP) for gallstone disease 
(n=4369), colonoscopy for inflammatory bowel disease (IBD; 
n=19 330) and colonoscopy for colorectal cancer screening 
(n=22 149) were submitted to five suitable clinical indicators 
per treatment. The percentage of all patients who met all five 
criteria was 54%±9% (SD) for ERCP treatment. For IBD this 
was 47%±7% of the patients, and for colon cancer screening 
this number was 85%±14%.
Conclusion This study shows that reusing data obtained 
from hospital information systems combined with clinical 
indicator definitions can be used to express short-term 
outcomes using the concept of Textbook Outcome without 
any excess registration. This information can provide 
meaningful insight into the clinical care trajectory on 
the level of individual patient care. Furthermore, this 
concept can be applied to many clinical trajectories within 
gastroenterology and beyond for monitoring and improving 
the clinical pathway and outcome for patients.
IntrOduCtIOn
background
Indicators for measuring healthcare quality 
can be divided into three main groups: 
structure indicators, clinical indicators and 
genuine health outcomes.1–3 Structure indi-
cators focus on infrastructure and the pres-
ence of protocols and guidelines. Clinical 
indicators largely focus on the presence 
of evidence-based treatment and adverse 
events like infection or readmission rates 
directly impacting the individual patient. 
Finally, genuine health outcomes consist of 
patient-reported health and quality of life 
after receiving care. Although genuine health 
outcomes are considered to be the most valu-
able indicators, these health outcomes are 
however mostly unavailable for most diseases. 
Moreover, collecting data concerning 
genuine health outcomes requires substan-
tial effort, is time consuming and usually not 
routinely part of standard care in most hospi-
tals. Although clinical indicators provide inad-
equate information on long-term outcome, 
they can provide useful information on the 
clinical path of individual patients. Moni-
toring clinical indicators can be used to 
improve the quality of healthcare4 and bears 
most value when analysed in a combination 
of multiple indicators, due to the multidi-
mensional nature of most diseases.5 
strengths and limitations of this study
 ► The data and analyses were obtained from existing 
data from hospital information systems.
 ► The  approach used in this study is applicable for 
evaluating various interventional processes.
 ► The study does not provide insight into post-
discharge outcomes.
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Textbook Outcome (TO) is a composite measure of 
clinical process indicators. TO is realised for patients for 
whom all desired short-term health indicators are met.6 
This approach enables a simple comprehensive summary 
of clinical care, and an in-depth analysis to get clinical 
insight into daily practice, per patient group and indi-
cator, all the way down to the clinical pathway per indi-
vidual patient. The approach of TO is particularly suited 
for clinical interventions (surgery, invasive diagnostics) 
and was previously used in a study performed in the 
Netherlands in patients undergoing colon resection due 
to colon cancer.6 The concept was also used in the form of 
a questionnaire in which patients reported their consid-
erations in the choice of a hospital,7 in patients with 
oesophagogastric cancer in need of surgery,8 and elective 
aneurism surgery.9 However none of these studies used 
existing data primarily used for reimbursement.
Objective
The objective of this study is to develop a model for moni-
toring short-term outcome of clinical care trajectories for 
hospitals in the Netherlands using data obtained from 
hospital information systems. The model is expected 
to successfully identify hospital variation on short-term 
outcomes on a large scale in a feasible and reproductive 
manner. In order to assess the discriminative value of the 
indicators used, the specificity score per indicator will be 
calculated.
In order to establish these objectives we further elon-
gate on previous approaches using TO, and apply this 
means of clinical pathway measurement on a larger scale 
based on clinical indicators for high-volume treatments. A 
TO was defined for three different treatments performed 
by gastroenterologists, consisting of at least five evidence-
based indicators as reviewed by an undisclosed panel of 
Figure 1 Flow chart of included hospitals and corresponding patient trajectories. *Hospitals affiliated with LOGEX are included 
in this study. ERCP, endoscopic retrograde cholangiopancreatography; IBD, inflammatory bowel disease. 
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Dutch gastroenterologists. In order to give a valid repre-
sentation of the care patients received in any included 
hospital, these indicators should cover as many stages of 
care as the data allow. This study aims to include indicators 
covering preprocedural, procedural and postprocedural 
care. The value of clinical indicators for patients in need 
of an endoscopic retrograde cholangiopancreatography 
(ERCP) due to gallstone disease will serve as an example 
in this study, focusing on the treatment trajectory prior, 
during and after ERCP. Furthermore, clinical indicators 
will be applied on two other major gastrointestinal treat-
ments based on the registration of available operational 
care activities. While analysing a great number of treat-
ments and providing a clear but comprehensive measure 
of the proportion of patients who have reached a TO, a 
new approach of assimilating existing data is exerted.
MethOds
study design
This study was reported in accordance with the Strength-
ening the Reporting of Observational Studies in Epide-
miology statement for reporting observational studies.10
The potential of TO was assessed by choosing three 
high-prevalent gastrointestinal diagnoses requiring endo-
scopic intervention. The first trajectory included patients 
with the diagnosis of ‘gallstone disease’ who under-
went ERCP for stone extraction. The second trajectory 
included patients who underwent at least one colonos-
copy for ‘colorectal cancer screening’. The third trajec-
tory included patients with ‘Inflammatory bowel disease’ 
(IBD), who also underwent a colonoscopy.
setting and data sources
The data set was retrieved from the benchmark data-
base owned by LOGEX (Amsterdam, The Netherlands). 
This database contains specific care activities and treat-
ment characteristics registered within the hospital infor-
mation system from hospitals associated with LOGEX. 
Each of these data sets is carefully validated in cooper-
ation with hospital information technology specialists, 
medical specialists and LOGEX. This validation process 
includes comparison with previous data deliveries (to 
identify unexpected outliers) and comparison of outpa-
tient contacts, inpatient contact and operations with the 
electronic patient records of the hospital. The retrieved 
benchmark database includes a wide variety of informa-
tion, such as, but not limited to: start and end dates of 
treatment, doctor–patient contacts, performed endo-
scopic, radiologic or laboratory diagnostics, surgical 
intervention, time of admission and days of inpatient 
stay. These activities per patient combine into care prod-
ucts (so called ‘DBC-DOT Zorgproducten’), comparable 
with diagnosis-related groups, which are primarily used 
for structuring and reimbursement of delivered care 
to healthcare providers. A recent study has shown that 
administrative data are a valid venue of data, and can 
be used for quality assessment of healthcare in cardiac 
patients.11 In 2015, the total number of hospitals in the 
Netherlands was 83, of which 62 were included in this 
study (75%); academic hospitals were excluded as will be 
discussed in the Discussion section, as well as four hospi-
tals without a gastrointestinal department. An overview of 
the selection of included hospitals per treatment is illus-
trated in figure 1.
study size and participants
All patients (n=45 848) with one of the three defined 
trajectories discharged between 1 January 2015 and 
31 December 2015 were evaluated. By definition, all 
patients were discharged within 42 days after interven-
tion and inpatient stay (related to reimbursement regu-
lations). All analysed patient trajectories were required 
to have at least one ‘core’ care intervention registered 
for their diagnosis; for gallstone disease this was the 
ERCP activity, and for IBD and colon cancer screening 
this core activity was the colonoscopy. For example, to 
be included in the analysis of ‘gallstone disease’, patients 
were required to fulfil the following inclusion criteria: (1) 
patients were diagnosed with gallstone disease, (2) were 
treated by a gastroenterologist and (3) underwent at least 
one ERCP for stone extraction (being the core activity), 
and (4) patient was discharged in 2015; there were no 
Table 1 Overview of the criteria per treatment structured by preprocedural, procedural and postprocedural indicators
Diagnosis
Treatment/core 
activity Volume
Preprocedural 
indicators
Procedural 
indicators
Postprocedural 
indicators
Choledocholithiasis
(Gallstone disease)
ERCP 4369 patients;
51 hospitals
Doctor–patient contact 
prior to ERCP20 21
Maximum number of 
ERCP is 1.22–24
Inpatient stay 
maximum 7 days25
No CT after ERCP26
No readmission within 
30 days27
Colorectal cancer 
screening
Colonoscopy 22 149 patients;
53 hospitals
Doctor–patient contact 
prior to colonoscopy28 29
No CT colon30
No lab tests31 32
No hospital admission33 34
No ER admission after 
colonoscopy35
Morbus Crohn and 
colitis ulcerosa (IBD)
Colonoscopy 19 330 patients;
62 hospitals
Maximum 56 days 
between first consult 
and colonoscopy36
Maximum number of 
colonoscopy is 1.
Inpatient stay 
maximum 3 days37 25
Doctor–patient counselling 
after colonoscopy38
No ER admission after 
colonoscopy35
ER, emergency room; ERCP, endoscopic retrograde cholangiopancreatography; IBD, inflammatory bowel disease. 
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additional exclusion criteria for patients. An overview of 
the selection of included patients per treatment is illus-
trated in figure 1; all diagnoses and used indicators are 
shown in table 1.
Variables
Extensive literature search was conducted prior to 
defining TO indicators. The indicators listed in table 1 
show the selected criteria to assess the clinical outcomes 
of ERCP, colorectal cancer screening and IBD. The selec-
tion choice of the clinical indicators is described in the 
online supplementary appendix in more detail.
Outcome definition
This study’s primary goal was to determine the varia-
tion among hospitals’ treatment score. For each patient 
treated, we determined if the treatment was considered 
to conform with TO—a binary outcome score (1/0). A 
patient was considered TO when all five indicators were 
met; if one or more of the five indicators were not met, 
the treatment was not considered TO. The selected set of 
indicators was applied to all patients, regardless of their 
background or medical complexity. The hospital score per 
treatment consists of every individual patient accumulated 
into a total score illustrated in a percentage of patients 
who have reached TO in the corresponding hospital: the 
TO score (%) is the quotient of total number of patients 
treated while fulfilling all five indicators (numerator) and 
the total number of treated patients in that hospital for 
that intervention (denominator). The indicators in the 
TO scope range from the first outpatient contact with the 
gastroenterologist up to the last registered care activity in 
the care trajectory, usually being a consult to check-up on 
the patient after the treatment to conclude the care cycle. 
If no new care activity is registered for a patient related to 
this intervention after patient discharge, the care trajec-
tory closes automatically.
statistical methods
The clinical indicators were assessed for each patient and 
the product of all clinical indicators resulted in the number 
and proportion of patients for whom all desired outcomes 
were realised and thereby a ‘Textbook Outcome’ was 
achieved. Per treatment and for each hospital, the propor-
tion of patients with a ‘Textbook Outcome’ was calculated.
Figure 2 Distribution of the scores per indicator shown for 53 hospitals: (A) distribution of scores on doctor–patient contact 
prior to ERCP, (B) no second ERCP, (C) inpatient stay, (D) no CT scan after ERCP, (E) no readmission within 30 days, and (F) 
product of all criteria, defined as Textbook Outcome. ERCP, endoscopic retrograde cholangiopancreatography. 
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To assess the impact of clinical indicators where the 
total TO was not met (TO=0), the specificity of each 
indicator was determined. The mean specificities across 
hospitals were depicted along with the percentage of TO 
that was not met (score=0) in order to provide increasing 
discriminative value of each singular indicator.
Second, a pairwise comparison between TO score on 
hospital level and score per indicator was performed per 
treatment to assess the relationship between reported 
score per hospital on individual indicators and total TO 
score. The relation is expressed in Pearson’s correlation. 
Additionally, pairwise comparison between clinical indi-
cators on hospital level was assessed. Pearson’s correla-
tion coefficient >0.7 was considered a strong correlation. 
The variation in score among hospitals is displayed by the 
SD. Statistical analyses were performed in Excel and SPSS 
V.25.
results
descriptive data
In total, 62 of the LOGEX-affiliated hospitals were 
included in this study (figure 1). For the ERCP trajectory 
a total number of 4369 ERCP patients treated in 51 hospi-
tals were included, of which 41.5% were male; and the 
average age was 66±18 years (SD). For the IBD colonos-
copy subgroup a total of 19 330 patients were included, 
45.0% were male; the average age was 48±17 years (SD). 
For colon cancer screening with a total of 22 149 patients, 
60.4% were male; the average age was 67±4 years (SD).
Outcome data and main result
The average TO score (score=1) for ERCP due to gall-
stone disease was 54%, with an SD of 9%. Accordingly, 
54% of 4369 unique patient trajectories have met all five 
criteria: doctor–patient contact prior to ERCP, not more 
than one ERCP, inpatient stay equal or shorter than 
7 days, no CT scan after ERCP and no readmission within 
30 days. Individual scores per indicator are illustrated 
in figure 2A–F; average score per indicator ranged from 
96% (no readmission within 30 days after ERCP) to 79% 
(length of stay does not exceed 7 days).
Each indicator was assessed in closer detail with regard 
to specificity in order to assess discriminative value. 
Figure 3A–C illustrates the specificity and variance 
between the TO score and each individual indicator. For 
patients who underwent an ERCP, indicator 5 (no read-
mission within 30 days) shows the lowest variance, and 
therefore is influencing the hospital’s total TO score the 
least. Indicator 3 (inpatient stay <7 days), however, shows 
the largest variance.
Figure 4A–F illustrates the association between the total 
TO score on hospital level and the hospital score per 
individual indicator. The calculated Pearson’s correla-
tion coefficient depicts the correlation between the 
score per individual indicator on hospital level and the 
total TO score. The statistical correlation for the score 
on doctor–patient contact with the total TO score proved 
weak-moderate positive (r=0.38). The correlation for 
scores on readmission (r=0.56) and no CT scan (r=0.62) 
were higher than with patient contact, being considered 
as a moderate positive linear relationship. The correla-
tion for scores on the indicators’ inpatient stay ≤7 days 
(r=0.74) and no second ERCP (r=0.80) proved strong 
positive. Pairwise comparison of the two indicators with 
highest correlation with total TO score on hospital level 
gives a weak correlation of r=0.55 (figure 4F).
The average TO score for IBD was 47%, with an SD of 
7%. Accordingly, 47% of 19 330 unique patient trajecto-
ries in 62 hospitals met all five criteria: time between first 
consult and colonoscopy does not exceed 56 days, the 
amount of colonoscopies is not more than one, inpatient 
stay equal or shorter than 3 days, no emergency room (ER) 
admission after colonoscopy and doctor–patient counsel-
ling afterwards. Individual scores per indicator are shown 
Figure 3 Specificity score per indicator. (A) ERCP for (1) doctor–patient contact prior to ERCP, (2) no second ERCP, (3) 
inpatient stay, (4) no CT scan after ERCP, (5) no readmission within 30 days, and per cent of all patients not meeting the five 
criteria. (B) IBD colonoscopy: (1) distribution of time scores between first consult and colonoscopy, (2) no second colonoscopy, 
(3) inpatient stay, (4) no emergency room (ER) admission after colonoscopy, (5) follow-up doctor–patient consult after 
colonoscopy, and per cent of all patients not meeting the five criteria. (C) Colon screening colonoscopies: (1) doctor–patient 
consult before colonoscopy, (2) no CT scan indicating complications, (3) no laboratory diagnostics indicating complications, 
(4) no inpatient admission after colonoscopy, (5) no ER admission after colonoscopy, and per cent of all patients not meeting 
the five criteria. ERCP, endoscopic retrograde cholangiopancreatography; IBD, inflammatory bowel disease; TO, Textbook 
Outcome. 
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in figure 5A–F; average score per indicator ranged from 
68% (time between first consult and colonoscopy does 
not exceed 56 days) to 97% (no second colonoscopy in 
clinical pathway). Indicator R values ranged from a weak 
r=0.02 (no CT scan after colonoscopy) to a moderate 
r=0.57 (doctor–patient contact prior to colonoscopy) 
positive correlation.
The average TO score for colorectal cancer screening 
was 85%, with an SD of 14%. Accordingly, 85% of 22 149 
unique patient trajectories in 53 hospitals met all five 
criteria: doctor–patient contact prior to colonoscopy, no 
CT colon and no laboratory tests indicating complica-
tions, no inpatient admission after colonoscopy and no 
ER admission afterwards. Individual scores per indicator 
are shown in figure 6A–F average score per indicator 
range from 93% (doctor–patient contact prior to colo-
noscopy) to 100% (no ER admission after colonoscopy). 
Again, indicator R values ranged from a weak r=0.17 (no 
second colonoscopy) to a moderate r=0.68 (maximum 
56 days waiting period) positive correlation.
Figure 4 Correlation between the total Textbook Outcome score and the individual indicators (A) doctor–patient contact 
prior to ERCP, (B) no second ERCP, (C) inpatient stay, (D) no CT scan after ERCP, (E) no admission within 30 days, and 
(F) the relation between hospital scores on no second ERCP and inpatient stay ≤7 days. ERCP, endoscopic retrograde 
cholangiopancreatography. 
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The total number of 4369 ERCPs performed for gall-
stones included in this research covers 87% of the total of 
5000 reimbursed ERCPs performed in the Netherlands in 
2015*. With 19 330 patients, the total amount of colonos-
copies for IBD covers 75% of the total in the Netherlands, 
while the 22 149 patients for screening colon cancer 
IBD cover 76% of the Netherlands in 2015.12
dIsCussIOn
Key results
With the use of TO, departments and physicians will be 
able to evaluate and compare their clinical outcomes with 
their peers throughout the entire country. Reporting the 
composite measure of TO shows added value with regard 
to points of interest for the total clinical pathway. The 
composition of TO adds most value when chosen indi-
cators do not overlap and add discriminative value, as is 
depicted in figure 3. With this model, a representable 
benchmark can be compiled for meaningful comparison 
between medical centres to monitor improvement over 
the years. Pinpointing underperforming segments of 
clinical care in comparison to their peers is among the 
possibilities.
To the same extent, it is possible as well to identify ‘best 
in class’ departments who might serve as an example for 
horizontal improvement. TO scores can be cross-refer-
enced against produced volume in order to analyse the 
influence of volume per hospital on the score in terms of 
clinical outcomes. In this study, we show that available and 
existing registration data for declaration purposes can be 
used for monitoring and evaluation of clinical pathways 
in high-prevalent treatments. While this study does not 
investigate a relation between volume per hospital and 
total score in the investigated diagnosis, these results 
can be integrated in future studies on volume quota per 
treatment.13 For improving local TO scores, the Pearson’s 
Figure 5 Distribution of the scores per indicator shown in 62 hospitals for inflammatory bowel disease (IBD): (A) distribution 
of time scores between first consult and colonoscopy, (B) no second colonoscopy, (C) inpatient stay, (D) no ER admission after 
colonoscopy, (E) follow-up doctor–patient consult after colonoscopy, (F) product of all criteria, defined as Textbook Outcome. 
ER, emergency room.
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correlation coefficient can assist in determining which 
indicator is most dominant for defining the total TO 
score; for ERCP this would be focusing on reducing rein-
tervention (figure 4).
limitations
While facing a patient population with an above average 
medical complexity, it is more likely to result in longer 
overall inpatient care and/or a higher complication rate. 
Comparing hospital scores as in this study assumes compa-
rable medical complexity among the analysed hospitals. 
Future studies have to investigate to what extent medical 
complexity and comorbidity (Charlson score) variation 
will influence TO scores.14 The possibility that patients 
receive care for the same condition (reintervention) in 
a different hospital cannot be ruled out. However, in the 
experience of the doctors who were involved in develop-
ment of the indicators, the vast majority of these rein-
terventions take place in the same hospital. The current 
study does not include academic centres as there is an 
insufficient amount of academic hospitals in the database 
under study. Therefore, we are unable to compare the 
results of these hospitals with their peers or differentiate 
in scores between academic centres and non-academic 
centres.
While this study is based on indicator scores on 
patient level, we emphasise that TO focuses on clinical 
indicators and does not take patient-related outcome 
measurement (PROM) or patient-related experience 
measurement into account. Combining short and long-
term outcomes is an interesting next step; however, 
studies show that consistently collecting patient-re-
ported outcomes (PROMs) faces barriers,15 with the 
main issue being the technological limits of integrating 
an electronic health record on a platform that collects 
PROMs to rapidly analyse data. Hesitant healthcare 
providers may even be the largest operational barrier, 
Figure 6 Distribution of the scores per indicator shown in 53 hospitals for colon cancer screening: (A) distribution of 
doctor–patient consult before colonoscopy, (B) no CT scan indicating complications, (C) no laboratory diagnostics indicating 
complications, (D) no inpatient admission after colonoscopy, (E) no ER admission after colonoscopy, (F) product of all criteria, 
defined as Textbook Outcome. ER, emergency room.
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with the large amount of time-consuming tasks already 
being part of their daily routine.15 When taking these 
factors into consideration, the advantages of analysing 
clinical indicators over PROMs are evident. The 
suggested combination of indicators per trajectory is 
shown valuable on hand, but further research is neces-
sary to evaluate the impact of patient characteristics 
including age, gender and comorbidity. By adding indi-
cators concerning case mix, an even more proficient way 
of insight can be provided for physicians. We would like 
to stress that the results do not implicate that patients 
who do not meet all indicators have been treated incor-
rectly. Certain medical complexity can be a valid reason 
to divert from TO or any other guidance protocols, if 
doing so benefits the individual patient. TO’s potential 
lies in identifying and interpreting significant differ-
ences on a group level, rather than advocating indica-
tor-driven clinical decision-making.
Focusing on improving average score on TO will 
optimise patient care, and probably reduce healthcare 
costs.16 Cost-effectiveness of healthcare is an important 
debate in both the Dutch and worldwide healthcare.17 18 
Unchecked expenses are to be increasing significantly in 
the upcoming years on the demand side due to the ageing 
of the population. On the supply side, new expensive 
medical technology and medication to treat the chron-
ically ill patient, for example, with a malignancy, will 
be available. Although these developments are widely 
encouraged, it also faces economic and operational chal-
lenges. The healthcare sector can aggress these challenges 
when using advanced data analytics as portrayed before in 
other sectors such as industry and aviation. The potency 
of improvement that can be reached by applying such a 
strategy of developing an integral chain of result-oriented 
indicators is evident.19
Generalisability
The external validity of this study’s methods is well suited 
beyond gastroenterology when used in the Netherlands 
or any country with similar forms of hospital information 
system data available. While the availability of data varies 
per country, the objective of this study to use existing data 
to improve providing healthcare can still be pursued.
COnClusIOn
This study shows that applying TO to existing data provides 
valuable insight into variance of daily clinical practice on 
a large scale, without additional time-consuming registra-
tion. This method of TO based on hospital information 
system data can be applied to many clinical trajectories 
for monitoring and improving the clinical pathway and 
outcome for patients.
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